NCT00784524

Phase II Study of Allo LMI Vaccine With IL-2 for Stable Metastatic Breast Ca

A Phase II Study of Allogeneic Large Multivalent Immunogen (LMI) Vaccine and IL-2 for the Treatment of Stable Metastatic Breast Cancer

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 14 (actual)
• Sponsor: Masonic Cancer Center, University of Minnesota · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: Vaccines may help the body build an effective immune response to kill tumor cells. Aldesleukin may stimulate the white blood cells to kill breast cancer cells. Giving vaccine therapy together with aldesleukin may be a more effective treatment for metastatic breast cancer. PURPOSE: This phase II trial is studying how well giving vaccine therapy together with aldesleukin works in treating women with metastatic breast cancer.

Detailed description

OBJECTIVES: Primary * To determine the efficacy of allogeneic large multivalent immunogen (LMI) vaccine and aldesleukin, as defined by clinical benefit rate (percentage of patients demonstrating a complete response, partial response, or disease stabilization as assessed by RECIST criteria), in women with stable metastatic breast cancer. Secondary * To measure the immune response in patients treated with this regimen. * To determine the progression-free survival of patients treated with this regimen. * To determine the 1- and 2-year overall survival rates in patients treated with this regimen. * To determine the safety profile and toxicity of this regimen in these patients. OUTLINE: Patients receive allogeneic large multivalent immunogen (LMI) vaccine intradermally on day 1 and aldesleukin subcutaneously on days 7 and 8. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression after 2 courses of vaccine therapy resume the chemotherapy regimen for which prior disease stabilization was achieved. Beginning 2-4 days after completion of chemotherapy, patients receive one dose of LMI vaccine followed by aldesleukin on days 7 and 8. Patients achieving at least stable disease continue to receive LMI vaccine and aldesleukin as above. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Peripheral blood mononuclear cell samples are collected periodically for research studies. Samples are analyzed to assess the frequency of leukocyte subsets (including B cells, T cells, NK cells, and monocytes) via flow cytometry; frequency of T-regs (T cells that express CD4, CD25, and FoxP3); and responses to keyhole limpet hemocyanin and tetanus toxoid via ELISA assay. Other immunological studies are also performed. After completion of study therapy, patients are followed every 3 months.

Conditions

• Breast Cancer

Interventions

Type	Name	Description
BIOLOGICAL	allogeneic large multivalent immunogen breast cancer vaccine	Allogeneic large multivalent immunogen breast cancer vaccine (1 x 10\^7, 5-μm silica spheres) will be given as an intradermal injection every 28 days (+/- 3 days). Each vaccine dose will be 0.2 ml.
BIOLOGICAL	aldesleukin	Subcutaneous aldesleukin (10 x 10\^6 International Units) will be given on day 7 and day 8 after each LMI injection.

Timeline

• Start date: 2008-09-01
• Primary completion: 2014-07-01
• Completion: 2014-07-01
• First posted: 2008-11-04
• Last updated: 2019-06-06
• Results posted: 2019-06-06

Locations

1 site across 1 country: United States